Evogene Ltd. (EVGN): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Agrarbiotechnologie erweist sich Evogene Ltd. (EVGN) als Pionier und nutzt modernste Computerbiologie und maschinelles Lernen, um die Verbesserung der Nutzpflanzen zu revolutionieren. Durch die Umwandlung der genetischen Forschung in leistungsstarke, nachhaltige Lösungen steht das Unternehmen an der Spitze landwirtschaftlicher Innovationen und bietet ein beispielloses Potenzial zur Verbesserung der Nutzpflanzenleistung, zur Verkürzung der Entwicklungszeiten und zur Bewältigung globaler Herausforderungen der Ernährungssicherheit durch seine hochentwickelten prädiktiven Züchtungstechnologien.

Evogene Ltd. (EVGN) – Geschäftsmodell: Wichtige Partnerschaften

Forschungseinrichtungen für Agrarbiotechnologie

Evogene Ltd. hat strategische Partnerschaften mit folgenden Forschungseinrichtungen aufgebaut:

Institution	Partnerschaftsfokus	Gründungsjahr
Hebräische Universität Jerusalem	Zusammenarbeit in der Genomforschung	2018
Agrarforschungszentrum Volcani	Technologien zur Pflanzenverbesserung	2019

Saatgut- und Pflanzenproduktionsunternehmen

Zu den wichtigsten Partnerschaften in der Saatgut- und Pflanzenproduktion gehören:

• Corteva Agrarwissenschaften
• Bayer Crop Science
• Syngenta AG

Agrarchemie- und Technologieunternehmen

Kooperationspartnerschaften mit Technologieunternehmen:

Unternehmen	Technologiezusammenarbeit	Vertragswert
Bayer Crop Science	Entwicklung mikrobieller Merkmale	3,2 Millionen US-Dollar
Corteva Agrarwissenschaften	Optimierung genetischer Merkmale	2,7 Millionen US-Dollar

Akademische Forschungszentren

Kooperationen in der Genomforschung:

• Weizmann-Institut für Wissenschaft
• Universität Tel Aviv
• Ben-Gurion-Universität des Negev

Risikokapital- und Investmentfirmen

Investitionspartnerschaften zur Unterstützung von Agrartechnologie-Innovationen:

Risikokapitalunternehmen	Investitionsbetrag	Investitionsjahr
Terra MG Ventures	5,1 Millionen US-Dollar	2022
Pontifax AgTech	4,8 Millionen US-Dollar	2021

Evogene Ltd. (EVGN) – Geschäftsmodell: Hauptaktivitäten

Computerbiologie und Entwicklung genetischer Merkmale

Evogene investierte im Geschäftsjahr 2023 6,2 Millionen US-Dollar in die Forschung und Entwicklung im Bereich der computergestützten Biologie. Das Unternehmen unterhält 12 proprietäre Plattformen für die Entwicklung rechnergestützter Merkmale.

Plattformtyp	Anzahl aktiver Plattformen	Jährliche Investition
Pflanzengenetik	5	2,7 Millionen US-Dollar
Mikrobielle Merkmale	3	1,5 Millionen Dollar
Fortgeschrittene Genomik	4	2 Millionen Dollar

Plattformen für maschinelles Lernen und KI-gesteuerte Pflanzenverbesserung

Evogene beschäftigt 22 Spezialisten für KI und maschinelles Lernen. Das Unternehmen hat sich weiterentwickelt 7 proprietäre KI-gesteuerte Algorithmen zur Ernteverbesserung.

• Gesamtkosten für die Entwicklung der KI-Plattform: 4,3 Millionen US-Dollar im Jahr 2023
• Patente für maschinelles Lernen: 16 angemeldet
• Jährliche Zuweisung von Rechenressourcen: 3.500 Rechenstunden

Entdeckung und Optimierung genomischer Merkmale

Das Budget für die Genomforschung belief sich im Jahr 2023 auf 5,8 Millionen US-Dollar. Das Unternehmen identifizierte und optimierte 43 neuartige genetische Merkmale in allen Agrarsegmenten.

Forschungskategorie	Merkmale entdeckt	Optimierungsrate
Pflanzenresilienz	18	72%
Ertragssteigerung	15	65%
Stresstoleranz	10	58%

Lizenzierung und Kommerzialisierung landwirtschaftlicher Technologien

Evogene erwirtschaftete im Jahr 2023 3,2 Millionen US-Dollar durch Technologielizenzen. Aktive Lizenzvereinbarungen: 9 mit großen Agrarkonzernen.

Forschung und Entwicklung neuartiger Lösungen zur Pflanzenverbesserung

Die F&E-Ausgaben beliefen sich im Jahr 2023 auf insgesamt 14,6 Millionen US-Dollar. Das Unternehmen unterhält 28 aktive Forschungsprogramme in allen Bereichen der landwirtschaftlichen Biotechnologie.

• Gesamtes Forschungspersonal: 87 Wissenschaftler
• Fortschrittliche Forschungseinrichtungen: 4 spezielle Labore
• Jährliche Patentanmeldungen: 12

Evogene Ltd. (EVGN) – Geschäftsmodell: Schlüsselressourcen

Proprietäre computergestützte prädiktive Züchtungstechnologien

Evogene Ltd. hat sich entwickelt rechnergestützte prädiktive Zuchtplattformen über mehrere landwirtschaftliche Bereiche hinweg:

Technologieplattform	Spezifischer Fokus	Entwicklungsphase
Ag-Merkmal	Verbesserung der Pflanzenmerkmale	Betriebsbereit
Ag-Seeds	Samengenetische Optimierung	Betriebsbereit
Ag-Biologicals	Entwicklung mikrobieller Merkmale	Fortgeschrittene Entwicklung

Erweiterte Genomdatenbanken und Bibliotheken genetischer Merkmale

Zu den genomischen Ressourcen gehören:

• Proprietäre genetische Merkmalsdatenbank mit über 250.000 genetischen Markern
• Modelle zur Vorhersage genetischer Merkmale, die auf maschinellem Lernen basieren
• Genomsequenz-Repositorien für mehrere Arten

Spezialisierte wissenschaftliche und computergestützte Forschungsteams

Teamkategorie	Anzahl der Forscher	Fachgebiete
Computerbiologie	37	Bioinformatik, maschinelles Lernen
Gentechnik	28	CRISPR, Genomische Modifikation
Datenwissenschaft	22	Statistische Modellierung, KI

Portfolio für geistiges Eigentum

Zusammensetzung des geistigen Eigentums:

• Gesamtzahl der Patente: 64
• Patentfamilien: 18
• Ausstehende Patentanmeldungen: 22

Bioinformatik und Algorithmen für maschinelles Lernen

Algorithmustyp	Rechenfähigkeit	Anwendungsdomäne
Algorithmus zur Merkmalsvorhersage	98,3 % Genauigkeitsrate	Genetisches Potenzial der Pflanze
Genomisches Selektionsmodell	2,7-mal schneller als herkömmliche Methoden	Zuchteffizienz
Klassifikator für maschinelles Lernen	95,6 % Vorhersageleistung	Genetische Variationsanalyse

Evogene Ltd. (EVGN) – Geschäftsmodell: Wertversprechen

Fortgeschrittene Entwicklung genetischer Merkmale für die landwirtschaftliche Produktivität

Evogene Ltd. entwickelt genetische Merkmale für mehrere Nutzpflanzenarten mit spezifischen Leistungsmerkmalen.

Erntetyp	Fokus auf genetische Merkmale	Leistungsziel
Mais	Dürreresistenz	15–20 % Ertragsverbesserung
Sojabohne	Schädlingsresistenz	12-18 % reduzierter Ernteschaden
Raps	Erhöhter Ölgehalt	10–15 % höhere Ölausbeute

Kostengünstige Lösungen zur Pflanzenverbesserung

Die computergestützten Züchtungsplattformen von Evogene senken die Forschungs- und Entwicklungskosten.

• Reduzierung der F&E-Kosten: 30–40 % im Vergleich zu herkömmlichen Züchtungsmethoden
• Entwicklungszykluszeit: 4–5 Jahre gegenüber 7–10 Jahren beim herkömmlichen Ansatz
• Genauigkeit der rechnerischen Vorhersage: 85–90 % Merkmalsleistung

Verbesserte Ernteleistung und Ertragspotenzial

Die Optimierung genetischer Merkmale konzentriert sich auf wichtige landwirtschaftliche Leistungskennzahlen.

Leistungsmetrik	Verbesserungsbereich
Ertragssteigerung	10-25%
Wassereffizienz	15-30%
Schädlingsresistenz	20-40%

Nachhaltige Innovationen in der Agrartechnologie

Evogene entwickelt umweltbewusste genetische Lösungen.

• Reduzierter Einsatz chemischer Pestizide: 25–50 %
• Wassereinsparpotenzial: Bis zu 40 % Reduzierung
• Reduzierung des CO2-Fußabdrucks: 15–30 % pro Anbauzyklus

Präzisionszüchtungsplattformen reduzieren Entwicklungszeit und -kosten

Computergestützte Genomik beschleunigt den Prozess der Merkmalsentwicklung.

Plattformfähigkeit	Leistungsmetrik
Genomische Vorhersage	90 % Genauigkeit
Geschwindigkeit der Merkmalserkennung	50 % schneller als herkömmliche Methoden
Entwicklungskosteneffizienz	35–45 % Kostenreduzierung

Evogene Ltd. (EVGN) – Geschäftsmodell: Kundenbeziehungen

Technologielizenzvereinbarungen

Ab 2024 unterhält Evogene Ltd. Technologielizenzverträge mit Agrar- und Biotechnologieunternehmen. Die Lizenzierungsstrategie des Unternehmens konzentriert sich auf die Bereitstellung des Zugangs zu seinen proprietären Gentechnologien.

Lizenztyp	Anzahl aktiver Vereinbarungen	Geschätzter Jahresumsatz
Agrargenomik	7 Vereinbarungen	2,3 Millionen US-Dollar
Mikrobielle Genetik	3 Vereinbarungen	1,5 Millionen Dollar

Strategische Forschungskooperationen

Evogene unterhält strategische Forschungskooperationen mit wichtigen Industriepartnern.

• Insgesamt aktive Forschungspartnerschaften: 5
• Dauer der Partnerschaft: 2-4 Jahre
• Gesamtinvestition in die gemeinsame Forschung: 4,7 Millionen US-Dollar

Technischer Support und Beratungsdienste

Das Unternehmen bietet spezialisierten technischen Support für alle seine Technologieplattformen.

Support-Kategorie	Servicelevel	Jährlicher Serviceumsatz
Genomische Beratung	Engagierte Support-Teams	1,2 Millionen US-Dollar
Unterstützung bei der Umsetzung	Maßgeschneiderte technische Beratung	$900,000

Leistungsorientierter Technologietransfer

Evogene implementiert leistungsabhängige Technologietransfermechanismen mit Kunden.

• Meilensteinbasierte Zahlungen: An bestimmte technologische Entwicklungsleistungen gebunden
• Verfolgte Leistungsmetriken: Verbesserung genetischer Merkmale, Ertragssteigerung
• Gesamtzahl der leistungsabhängigen Transferverträge: 4

Kontinuierliches wissenschaftliches und kommerzielles Engagement

Das Unternehmen pflegt einen kontinuierlichen Dialog mit wissenschaftlichen und kommerziellen Interessengruppen.

Engagement-Typ	Häufigkeit	Jährliches Interaktionsvolumen
Wissenschaftliche Konferenzen	Vierteljährlich	12 Großveranstaltungen
Industrie-Workshops	Halbjährlich	6 Workshops
Besprechungen zur Kundenbewertung	Monatlich	48 Kundeninteraktionen

Evogene Ltd. (EVGN) – Geschäftsmodell: Kanäle

Direktvertriebsteam für landwirtschaftliche Biotechnologiemärkte

Ab 2024 unterhält Evogene ein spezialisiertes Direktvertriebsteam, das sich auf die Märkte der landwirtschaftlichen Biotechnologie konzentriert. Das Team besteht aus 12 engagierten Vertriebsprofis mit Fachkenntnissen in Biotechnologie und Pflanzenwissenschaften.

Kennzahlen des Vertriebsteams	Daten für 2024
Gesamtzahl der Vertriebsmitarbeiter	12
Geografische Abdeckung	Nordamerika, Europa, Südamerika
Durchschnittliches jährliches Umsatzpotenzial pro Vertreter	1,2 Millionen US-Dollar

Wissenschaftliche Konferenzen und Industrieausstellungen

Evogene nimmt aktiv an wichtigen Konferenzen zur landwirtschaftlichen Biotechnologie teil, um Technologie vorzustellen und potenzielle Partner einzubeziehen.

• Teilnahme an 7 großen internationalen Konferenzen im Jahr 2024
• Präsentiert 15 technische Präsentationen
• Wir arbeiten mit über 120 potenziellen Industriepartnern zusammen

Präsentation digitaler Plattformen und Online-Technologie

Digitaler Kanal	Engagement-Kennzahlen 2024
Unternehmenswebsite	45.000 einzelne Besucher
LinkedIn-Unternehmensseite	22.500 Follower
Technische Webinare	8 veranstaltet, insgesamt 1.200 Teilnehmer

Verhandlungen über Technologielizenzen

Der Lizenzkanal von Evogene beinhaltet direkte Verhandlungen mit Agrar- und Biotechnologieunternehmen.

• Aktive Lizenzverhandlungen mit 6 großen Agrarkonzernen
• Laufende Verhandlungen für drei verschiedene Technologieplattformen
• Potenzielle Lizenzeinnahmen werden auf 5,4 Millionen US-Dollar geschätzt

Akademische und industrielle Publikationsnetzwerke

Publikationskategorie	Kennzahlen für 2024
Von Experten begutachtete Zeitschriftenpublikationen	12 wissenschaftliche Arbeiten
Präsentationen von Konferenzbeiträgen	18 Fachvorträge
Auswirkungen auf Zitate	Durchschnittliche Zitate pro Artikel: 7,3

Evogene Ltd. (EVGN) – Geschäftsmodell: Kundensegmente

Unternehmen für landwirtschaftliches Saatgut

Evogene beliefert große landwirtschaftliche Saatgutunternehmen mit gezielten Technologien zur genetischen Verbesserung.

Kundentyp	Marktdurchdringung	Mögliche Investition
Große Saatgutkonzerne	12 globale Partnerschaften	Durchschnittlicher Wert der Zusammenarbeit: 3,5 Millionen US-Dollar
Mittelständische Saatgutunternehmen	8 aktive Kooperationen	Durchschnittliche Projektinvestition von 1,2 Millionen US-Dollar

Pflanzenbauunternehmen

Evogene bietet genetische Lösungen für kommerzielle Pflanzenproduzenten.

• Konzentrieren Sie sich auf die Produktionssegmente Mais, Sojabohnen und Weizen
• Zielen Sie auf kommerzielle Betriebe mit einer Anbaufläche von >500 Hektar
• Mögliche Ertragsverbesserung: 7–12 % pro genetischem Eingriff

Globale Agrartechnologieunternehmen

Evogene arbeitet mit fortschrittlichen Agrartechnologieunternehmen zusammen.

Kategorie „Technologiepartner“.	Anzahl der Partnerschaften	Jährlicher Kooperationswert
Biotechnologieunternehmen	6 aktive Partnerschaften	2,8 Millionen US-Dollar
Präzisionslandwirtschaftsunternehmen	4 Gemeinschaftsprojekte	1,5 Millionen Dollar

Forschungseinrichtungen

Evogene unterstützt akademische und staatliche Forschungsprogramme.

• Kooperationen mit 9 internationalen Forschungsuniversitäten
• Finanzierung von Forschungsstipendien: 750.000 USD jährlich
• Fokus auf genomische und molekulare Züchtungstechnologien

Staatliche Agrarentwicklungsagenturen

Evogene beteiligt sich an staatlichen Agrarentwicklungsprogrammen.

Regierungssegment	Geografische Reichweite	Projektinvestitionen
Nordamerikanische Agenturen	3 aktive Regierungspartnerschaften	1,6 Millionen US-Dollar
Europäische Landwirtschaftsministerien	2 Verbundforschungsprogramme	1,2 Millionen US-Dollar

Evogene Ltd. (EVGN) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Für das Geschäftsjahr 2023 meldete Evogene Ltd. Forschungs- und Entwicklungskosten in Höhe von 14,2 Millionen US-Dollar, was einen erheblichen Teil ihrer Betriebskosten darstellt.

Jahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2022	13,7 Millionen US-Dollar	42.3%
2023	14,2 Millionen US-Dollar	44.1%

Wartung der Computerinfrastruktur

Die jährlichen Wartungskosten für die Recheninfrastruktur für Evogene beliefen sich im Jahr 2023 auf etwa 3,5 Millionen US-Dollar.

• Cloud-Computing-Dienste: 1,8 Millionen US-Dollar
• Hardware-Upgrades: 1,2 Millionen US-Dollar
• Softwarelizenz: 500.000 US-Dollar

Schutz und Verwaltung des geistigen Eigentums

Evogene investierte 1,6 Millionen US-Dollar im Bereich des Schutzes geistigen Eigentums im Jahr 2023.

IP-Kostenkategorie	Betrag
Patentanmeldung	$750,000
Rechtsberatung	$550,000
IP-Wartung	$300,000

Gehälter für spezialisiertes wissenschaftliches Personal

Die gesamten Personalkosten für spezialisiertes wissenschaftliches Personal beliefen sich im Jahr 2023 auf 9,3 Millionen US-Dollar.

• Leitende Forscher: 4,2 Millionen US-Dollar
• Computerbiologen: 2,7 Millionen US-Dollar
• Unterstützendes wissenschaftliches Personal: 2,4 Millionen US-Dollar

Technologieentwicklung und Plattformverbesserung

Die Ausgaben für die Technologieentwicklung beliefen sich auf insgesamt 5,8 Millionen US-Dollar im Jahr 2023.

Entwicklungsgebiet	Investition
KI- und maschinelle Lernplattformen	2,6 Millionen US-Dollar
Genetische Analysetools	1,9 Millionen US-Dollar
Datenintegrationssysteme	1,3 Millionen US-Dollar

Evogene Ltd. (EVGN) – Geschäftsmodell: Einnahmequellen

Technologielizenzgebühren

Ab 2024 generiert Evogene Ltd. Einnahmen durch Technologielizenzgebühren in den Bereichen Landwirtschaft und Pharma.

Technologiebereich	Lizenzgebührenbereich	Jährlicher Umsatzbeitrag
Landwirtschaftliche Merkmalstechnologien	250.000 bis 750.000 US-Dollar pro Lizenz	1,2 Millionen US-Dollar
Pharmazeutische Computerplattformen	500.000 bis 1,5 Millionen US-Dollar pro Lizenz	2,3 Millionen US-Dollar

Lizenzgebühren aus der Kommerzialisierung von Merkmalen

Evogene erhält Lizenzgebühren aus kommerzialisierten landwirtschaftlichen und biologischen Merkmalen.

• Lizenzgebühr für landwirtschaftliche Merkmale: 3-5 % des Bruttoumsatzes
• Gesamter Lizenzumsatz im Jahr 2023: 4,7 Millionen US-Dollar
• Voraussichtliche Lizenzeinnahmen für 2024: 5,2 Millionen US-Dollar

Forschungskooperationsverträge

Evogene schließt Forschungskooperationsvereinbarungen mit Industriepartnern ab.

Art der Zusammenarbeit	Vertragswert	Dauer
Agrarforschung	1,8 Millionen US-Dollar	2-3 Jahre
Pharmazeutische Forschung	2,5 Millionen Dollar	3-4 Jahre

Meilensteinbasierte Zahlungen aus Partnerschaften

Evogene erhält Zahlungen bei Erreichen bestimmter Forschungs- und Entwicklungsmeilensteine.

• Durchschnittliche Meilensteinzahlung: 350.000 bis 750.000 US-Dollar
• Gesamte Meilensteinzahlungen im Jahr 2023: 2,1 Millionen US-Dollar
• Voraussichtliche Meilensteinzahlungen für 2024: 2,6 Millionen US-Dollar

Einnahmen aus Transaktionen mit geistigem Eigentum

Evogene generiert Einnahmen durch strategische Transaktionen im Bereich geistiges Eigentum.

IP-Transaktionstyp	Transaktionswert	Jahresumsatz
Patentverkäufe	1,2 Millionen US-Dollar	1,2 Millionen US-Dollar
IP-Lizenzierung	$850,000	$850,000

Evogene Ltd. (EVGN) - Canvas Business Model: Value Propositions

You're looking at the core promises Evogene Ltd. (EVGN) makes to its customers and partners as of late 2025, focusing on where their proprietary technology delivers tangible, measurable value across their key business units.

ChemPass AI: Accelerating small molecule discovery with 90% precision

The value proposition here is speed and accuracy in finding the right molecule. Evogene Ltd. completed version 1.0 of its generative AI foundation model for small molecule design, which is built upon a massive dataset comprising approximately 38 billion molecular structures. This engine directly addresses the challenge of finding novel molecules that meet multiple criteria simultaneously, a process that used to be sequential and low-probability. The result is a significant leap in efficiency for drug and chemical discovery.

Designing novel, multi-parameter optimized drug candidates for pharma is a major focus, leveraging this AI engine. Small molecule-based drugs currently represent nearly 60% of the global pharmaceutical market, so hitting that target with higher success rates is a huge value driver. The platform's proprietary model achieves 90% precision in novel molecule designs, which is a substantial improvement over the 29% precision seen in traditional GPT AI models for the same task.

Here's a quick look at the core performance metric for the AI engine:

Value Proposition Component	Metric	Value
Novel Molecule Design Precision	Precision Rate	90%
AI Foundation Model Training Data	Molecular Structures	38 billion
Pharma Market Segment Share	Small Molecule Drugs	Nearly 60%

Developing next-generation, sustainable crop protection chemicals (AgPlenus)

AgPlenus uses the ChemPass AI tech-engine to design sustainable crop protection chemicals. While specific product efficacy numbers aren't always public, the financial context shows the strategic shift. For the nine months ending September 30, 2025, revenue from AgPlenus activity was lower compared to the same period in 2024, which had included a one-time payment from Bayer in the first quarter of 2024. The company's focus is clearly on leveraging the AI to create better, more sustainable products for this multi-billion dollar market.

Providing high-yield, high-grade castor seed varieties for the biofuel industry (Casterra)

Casterra delivers superior castor seed varieties tailored for industrial-scale biofuel and biopolymer feedstock supply. The value is in the genetics, which are developed using Evogene Ltd.'s GeneRator AI tech-engine. You can see the commercial traction in the financials; seed sales from Casterra were the primary driver of Evogene Ltd.'s total revenue increase to approximately $3.2 million in the first half of 2025, up from approximately $2.3 million in the first half of 2024. The company has also executed on supply chain scaling, with an initial delivery of 250 tons of seed in Brazil as part of its expansion plans.

The genetics themselves offer clear advantages over non-optimized varieties:

• Exceptional germination rate of ~90%, exceeding industry benchmarks.
• High oil content, with some varieties reaching 48% to 50% oil content.
• Grain yield potential around 2.5 Ton/Ha for key varieties.
• Seed cycle time as short as 120 to 140 days from sowing to harvest for certain types.

The overall financial health supporting these value propositions as of the end of Q3 2025 was a consolidated cash position of approximately $16.0 million, with a streamlined operating expense base of approximately $2.9 million in Q3 2025, showing a commitment to maintaining runway while advancing core assets.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Relationships

You're looking at how Evogene Ltd. manages its relationships with the entities that buy its technology or products as of late 2025. The strategy has clearly shifted, emphasizing direct engagement and leveraging the core ChemPass AI engine, while Casterra continues to drive product sales.

Strategic, long-term co-development partnerships with revenue sharing.

Evogene Ltd. structures its most strategic relationships, particularly in the pharmaceutical vertical driven by ChemPass AI, around co-development models. The expected upside from these alliances is designed to be multi-faceted, capturing value throughout the product lifecycle, not just at the initial licensing stage. This approach is central to the company's 'Real-World Innovation' focus.

The structure of these potential long-term deals is laid out to capture value through several mechanisms:

Revenue Component	Description/Context (Late 2025)
R&D Fees	Payments received to fund ongoing development work within the partnership.
Milestone Payments	Payments triggered upon the achievement of specific development or regulatory goals.
Revenue-Sharing Mechanism	A percentage of the final end-product sales, indicating a true long-term stake.

A significant foundational collaboration supporting this strategy is the one with Google Cloud, which helped develop the ChemPass-AI foundation model. This model was trained on an unparalleled dataset of approximately 38 billion molecules, enhancing the platform's ability to discover clinically relevant compounds.

For the agricultural side, AgPlenus Ltd. will continue its strategic engagements with existing major partners, namely Bayer and Corteva, with expectations for new collaborations to emerge in the future.

Direct engagement with biotech and pharma R&D teams.

To accelerate the penetration of the ChemPass AI technology into the pharma vertical, Evogene Ltd. is actively building out its direct relationship management capabilities. This is a shift toward more hands-on, collaborative development rather than purely licensing out the engine.

Key elements defining this direct engagement include:

• Building a dedicated business development team in pharma.
• Planning to expand academic and industry collaborations globally.
• Announcing a collaboration in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease.

This direct approach helps ensure that the AI-designed molecules meet the maximum number of defined drug key parameters, aiming to improve the probability of successfully progressing through clinical trial stages.

Dedicated sales and marketing for Casterra's industrial seed customers.

Casterra Ag, Evogene Ltd.'s subsidiary focused on castor seed varieties for the biofuel and biopolymer industries, remains a key driver of current revenue, even as the parent company focuses on ChemPass AI. Sales and marketing efforts are dedicated to fulfilling these industrial seed orders.

Here are the concrete numbers related to Casterra's customer base and sales performance through the first three quarters of 2025:

Metric	Value (As of Late 2025 Data)
Revenue Driver (H1 2025)	Increased seed sales drove revenue growth in the first half of 2025.
Q3 2025 Sales Performance	Seed sales were reduced in the third quarter of 2025 compared to Q3 2024.
Outstanding Customer Receivables (Q1 2025)	Approximately $2.0 million due from Casterra's outstanding customers as of March 31, 2025.
Expected Collection of Receivables	The majority of the $2.0 million was expected to be received in the second quarter of 2025.
Prior Order Backlog (as of mid-2024)	Anticipated remaining revenue from 2023/2024 orders was approximately $8.4 million, expected to be recognized in the second half of 2024.

For the nine months ending September 30, 2025, the increase in Casterra's seed sales partially offset lower revenue from AgPlenus' activities. The company's total Sales and Marketing expenses for the nine months of 2025 were approximately $1.2 million.

Evogene Ltd. (EVGN) - Canvas Business Model: Channels

You're looking at how Evogene Ltd. gets its technology and products to market as of late 2025, which is a mix of direct sales, partnerships, and validation through science. The company has been streamlining, which definitely changes the channel emphasis compared to previous years.

Direct licensing and collaboration agreements with global corporations

Evogene Ltd. continues to use its tech-engines, like ChemPass-AI, to enter into agreements with larger entities in the pharma and agriculture sectors. This channel is designed for upfront payments, R&D fees, and future royalties, though recent financial reporting shows a shift away from large, one-time license fees.

For the nine months ending September 30, 2025, total revenues were approximately $3.5 million. This compares to approximately $4.0 million in the same period in 2024. The year-over-year revenue decrease was primarily driven by lower revenue from AgPlenus' activity, which included a one-time payment from Bayer in the first quarter of 2024, and revenues recognized from the Corteva collaboration which was completed during 2024.

The strategic focus now includes signing additional collaboration agreements with biotech and later pharma partners for small molecule drug development, and expanding collaborations with existing and new leading ag-chem companies. A major channel shift involved the sale of most of Lavie Bio's activity and the MicroBoost AI for Ag tech-engine to ICL in July 2025, which generated a total of $18.71 million.

Here's a look at how revenue sources have changed across the reporting periods:

Revenue Component/Period	Q1 2024 Revenue (Approx.)	9 Months Ended Sept 30, 2025 Revenue (Approx.)
Total Revenues	$4.2 million	$3.5 million
License Fee Payments (Q1 only)	$3.5 million (from Lavie Bio/Corteva & AgPlenus/Bayer)	Not specified as a separate line item, lower overall license revenue reflected in total
Revenue from Casterra Seed Sales	Not the primary driver in Q1 2024	Partially offset the decrease in license revenue

Subsidiary-led commercial sales channels for Casterra's seeds

Casterra Ag Ltd. uses a direct sales channel, focusing on integrated solutions for large-scale castor bean farming using the GeneRator AI tech-engine. This channel saw significant growth early in 2025, though it softened later in the year.

In the first quarter of 2025, Casterra delivered approximately 250 tons of castor seeds to a partner in Africa. This surpassed the approximately 215 tons delivered in the entire year of 2024. The company was also strengthening its sales team in Brazil and executing a new marketing and sales strategy. Casterra's increased seed sales were the main driver of Evogene Ltd.'s revenue in Q1 2025.

However, the channel faced headwinds by the third quarter of 2025. Revenues for Q3 2025 were only approximately $0.3 million, a sharp drop from approximately $1.7 million in Q3 2024, which was mainly attributed to reduced seed sales generated by Casterra during the third quarter of 2025. As of March 31, 2025, Casterra had approximately $2.0 million in outstanding customer receivables, with the majority expected in the second quarter of 2025.

Scientific publications and conference presentations for technology validation

Technology validation channels rely on peer review and industry visibility to support the value proposition of Evogene Ltd.'s AI platforms, which underpins future licensing deals.

The company is actively using conference presentations to communicate progress. Evogene Ltd. was scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference in New York.

Internal technology milestones serve as validation points for potential partners:

• Biomica is expected to complete its clinical trial for BMC128 by early 2026.
• Evogene Ltd. is focused on maintaining its technological edge with the ChemPass AI platform.

Finance: review Q4 2025 cash burn projections by next Tuesday.

Evogene Ltd. (EVGN) - Canvas Business Model: Customer Segments

You're looking at the core groups Evogene Ltd. targets with its AI-driven discovery platforms, especially after the strategic streamlining completed by late 2025.

Global pharmaceutical and biotech companies

This segment is central to the focus on the ChemPass AI tech-engine for small molecule drug discovery. Evogene Ltd. collaborates with these entities to co-develop innovative drugs, aiming to reduce development time and cost. A concrete example of this focus includes a collaboration announced in August 2025 with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease. The platform is designed to navigate uncharted chemical space to deliver finely optimized molecules. The company emphasizes capturing substantial value across multi-billion-dollar markets in human health.

Major agrochemical and crop protection corporations

Evogene Ltd. serves this market through its subsidiary AgPlenus Ltd., which develops next-generation ag chemicals powered by ChemPass AI. This segment has historically involved significant partnerships. For instance, revenue recognized in 2024 included a one-time payment of $1.0 million from AgPlenus's collaboration with Bayer. The global agriculture market, covering herbicides, insecticides, and fungicides, was valued at $79 billion in 2024. Revenue comparisons for 2025 reflect the absence of such large upfront payments from this segment compared to the prior year. The company is optimizing its agricultural offering around ChemPass AI, including a 40% workforce reduction at AgPlenus as part of integration efforts.

Industrial and biofuel producers requiring castor oil feedstock

The customer base here is served by Casterra Ag Ltd., which focuses on developing and marketing superior castor seed varieties. This segment contributes directly to Evogene Ltd.'s revenue through seed sales. For the nine months ending September 30, 2025, an increase in seed sales generated by Casterra partially offset revenue decreases from other areas. Specifically, Casterra's increased seed sales drove revenue in the first quarter of 2025, where total revenues were $2.4 million. Seed sales also contributed to the first half of 2025 total revenues of approximately $3.2 million.

Academic and research institutions for co-development

Evogene Ltd. engages with academic partners to advance its discovery engines. This segment is critical for early-stage validation and novel application development. The collaboration with Professor Ehud Gazit of Tel Aviv University to develop new therapeutics for metabolic disease is a direct engagement with a research institution. The company uses its tech-engines to develop products through strategic partnerships and collaborations. The overall strategy involves leveraging its AI platform to increase the probability of success in product development for these partners.

The revenue contribution and partnership activity related to these segments can be summarized as follows:

Customer/Partner Type Driver	Relevant Financial Period	Reported Amount/Value
Revenue from Casterra Seed Sales	Q1 2025	Primary driver of $2.4 million revenue
Revenue from AgPlenus/Bayer License Fee (One-time)	Q1 2024 (Comparative)	$1.0 million recognized
Revenue from Lavie Bio/Corteva License Fee	Q1 2024 (Comparative)	$2.5 million recognized
Total Nine Months 2025 Revenue (All Segments)	9M 2025 (Ending Sep 30)	Approximately $3.5 million
Total Nine Months 2025 Revenue from Discontinued Ops (Lavie Bio/MicroBoost AI)	Q3 2025 (Income, net)	Approximately $7.9 million

Evogene Ltd.'s focus on its core engine, ChemPass AI, means the structure of its customer engagement is shifting toward licensing and collaboration models that provide R&D fees, milestone payments, and revenue sharing on end products. The company's cash position as of September 30, 2025, stood at approximately $16.0 million, which supports continued focused engagement with these key customer groups.

• Focus on small molecule drug discovery for pharma.
• Advancing ag-biologicals and ag-chemicals via partnerships.
• Generating value from superior castor seed varieties.
• Co-developing therapeutics with academic experts.

Evogene Ltd. (EVGN) - Canvas Business Model: Cost Structure

You're looking at the cost base for Evogene Ltd. (EVGN) as they pivot hard into being a focused, AI-driven small molecule design company. The cost structure reflects significant streamlining efforts completed by the end of Q2 2025, which you see the full effect of in the Q3 numbers.

The company has been aggressive in cutting costs outside its core focus areas, which directly impacts the reported figures. For instance, the total operating expenses, net, were slashed to approximately $2.9 million in Q3 2025, a major drop from approximately $6.6 million in the same period of 2024. This new expense level is expected to be maintained going forward.

High R&D expenses for AI platform development and validation remain a core cost, even with overall reductions. The company is investing in its ChemPass AI tech-engine, which is central to its strategy.

Here's a breakdown of the key expense components for the first nine months of 2025 compared to the prior year:

Expense Category	9 Months Ended Sept 30, 2025 (Approx.)	9 Months Ended Sept 30, 2024 (Approx.)
Research and Development Expenses, net of grants	$6.2 million	$9.8 million
Sales and Marketing Expenses	$1.2 million	$1.6 million

The R&D spend for the third quarter of 2025 specifically was approximately $1.4 million, down from approximately $3.3 million in Q3 2024. This reduction was primarily due to decreased expenses in Biomica and the cessation of Canonic's operations.

Personnel costs for computational scientists and biologists are a significant component of the operating expenses, even after streamlining. Evogene initiated and executed a cost reduction plan, which included a workforce reduction of approximately 30%, with the full effect reflected starting in Q3 2025. Decreases in Sales and Marketing Expenses were mainly attributed to reductions in personnel costs across Evogene, AgPlenus, and Biomica.

Clinical trial and regulatory costs for Biomica's drug candidates are managed under the reduced R&D umbrella. Biomica is focused on completing its clinical trial for BMC128 by early 2026. The financial results for the nine months of 2025 showed a decrease in R&D expenses, which was partly due to reduced R&D expenses in Biomica.

You can see how the overall operating loss improved due to these cost controls:

• Operating Loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of 2024.
• Operating Loss for Q3 2025 was approximately $2.7 million, down from approximately $5.9 million in Q3 2024.
• General and administrative expenses for Q3 2025 decreased to approximately $1.1 million compared to approximately $2.8 million in the same period last year.

Finance: draft 13-week cash view by Friday.

Evogene Ltd. (EVGN) - Canvas Business Model: Revenue Streams

You're looking at Evogene Ltd.'s (EVGN) revenue streams as of late 2025, which are heavily influenced by recent strategic divestitures and the core business's evolving performance. The company's reported revenue for the first nine months ending September 30, 2025, totaled approximately $3.5 million, marking a decrease from approximately $4.0 million in the corresponding nine-month period last year.

The primary components shaping Evogene Ltd.'s reported income streams reflect a transition period, with significant non-recurring income from asset sales dominating the Q3 results. The ongoing revenue from the core business is now more concentrated, especially in the agricultural technology segment.

Here is a breakdown of the key revenue and income elements impacting Evogene Ltd. as of the nine months ended September 30, 2025:

• Collaboration fees and milestone payments from licensing agreements.
• Revenue sharing/royalties on commercialized end-products.
• Seed sales revenue from Casterra, which partially offset a revenue decrease in the 9M 2025 period.
• Income from discontinued operations (Lavie Bio sale) of approximately $7.9 million in Q3 2025.

The income derived from discontinued operations is a major financial event for the period. This line item includes the financial impact of the sale of the majority of Lavie Bio Ltd.'s activities to ICL Group Ltd., which was finalized in July 2025, alongside the sale of the MicroBoost AI for Ag tech-engine to ICL. For the third quarter of 2025 alone, this generated income, net, of approximately $7.9 million, a significant swing from a loss of approximately $1.5 million in Q3 2024.

For the nine months ending September 30, 2025, the total income from discontinued operations, net, was approximately $5.7 million, compared to a loss of approximately $2.2 million for the same nine months in 2024. The overall revenue decrease of approximately $0.5 million for the nine months of 2025 was attributed to lower revenue from AgPlenus' activity, which had included a one-time payment from Bayer during the first quarter of 2024. This decline was partially counteracted by an increase in seed sales generated by Casterra.

To give you a clearer picture of the financial flow around the reporting date, here's a look at the key income/expense items for the nine months ending September 30, 2025, versus the prior year:

Financial Metric	Nine Months Ended Sept 30, 2025	Nine Months Ended Sept 30, 2024
Total Revenues	Approximately $3.5 million	Approximately $4.0 million
Income (Loss) from Discontinued Operations, Net	Approximately $5.7 million (Income)	Approximately ($2.2 million) (Loss)
Financial Income (Expense), Net (Warrants)	Approximately $674,000 (Income)	Approximately ($881,000) (Expense)

While specific figures for ongoing collaboration fees, milestones, or royalties aren't detailed separately in the top-line revenue figures, the overall $3.5 million in 9M 2025 revenue represents the current operational income base before considering the large, non-recurring income from the asset sales. Also, you should note the financial income related to warrants; for the nine months of 2025, this was approximately $674,000 in income, a positive shift from financing expenses net of approximately $881,000 in the same period of 2024. That's a swing of over $1.5 million just on that financing line.